170 related articles for article (PubMed ID: 3192681)
1. Serum aminoterminal propeptide of type III procollagen: a potential predictor of the response to growth hormone therapy.
Tapanainen P; Risteli L; Knip M; Käär ML; Risteli J
J Clin Endocrinol Metab; 1988 Dec; 67(6):1244-9. PubMed ID: 3192681
[TBL] [Abstract][Full Text] [Related]
2. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; DiNero G
Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
[TBL] [Abstract][Full Text] [Related]
3. Long-term monitoring of treatment with recombinant human growth hormone by serial determinations of type III procollagen-related antigens in serum.
Danne T; Grüters A; Schnabel K; Burger W; L'Allemand D; Enders I; Helge H; Weber B
Pediatr Res; 1988 Feb; 23(2):167-71. PubMed ID: 3353159
[TBL] [Abstract][Full Text] [Related]
4. Growth velocity, growth hormone therapy, and serum concentrations of the amino-terminal propeptide of type III procollagen.
Trivedi P; Hindmarsh P; Risteli J; Risteli L; Mowat AP; Brook CG
J Pediatr; 1989 Feb; 114(2):225-30. PubMed ID: 2915282
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen in children with growth retardation.
Cinaz P; Hasanoglu E; Gökçora N; Dogukan S; Demir A
Mater Med Pol; 1994; 26(2):55-8. PubMed ID: 7745984
[TBL] [Abstract][Full Text] [Related]
6. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
[TBL] [Abstract][Full Text] [Related]
7. Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature.
Gascoin-Lachambre G; Trivin C; Brauner R; Souberbielle JC
Growth Horm IGF Res; 2007 Jun; 17(3):194-200. PubMed ID: 17321775
[TBL] [Abstract][Full Text] [Related]
8. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.
Sartorio A; Arosio M; Conti A; Ferrero S; Porretti S; Faglia G
J Endocrinol Invest; 1999 Mar; 22(3):169-75. PubMed ID: 10219883
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; Di Nero G
J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
[TBL] [Abstract][Full Text] [Related]
10. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy.
Tobiume H; Kanzaki S; Hida S; Ono T; Moriwake T; Yamauchi S; Tanaka H; Seino Y
J Clin Endocrinol Metab; 1997 Jul; 82(7):2056-61. PubMed ID: 9215272
[TBL] [Abstract][Full Text] [Related]
11. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects.
Amato G; Izzo G; La Montagna G; Bellastella A
Clin Endocrinol (Oxf); 1996 Jul; 45(1):27-32. PubMed ID: 8796135
[TBL] [Abstract][Full Text] [Related]
12. Collagen metabolites in the prediction of response to GH therapy in short children.
Tapanainen P; Knip M; Risteli L; Kemppainen L; Käär ML; Risteli J
Eur J Endocrinol; 1997 Dec; 137(6):621-5. PubMed ID: 9437226
[TBL] [Abstract][Full Text] [Related]
13. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.
Sartorio A; Conte G; Conti A; Masala A; Alagna S; Rovasio P; Faglia G
J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy.
Kubo T; Tanaka H; Inoue M; Kanzaki S; Seino Y
Bone; 1995 Oct; 17(4):397-401. PubMed ID: 8573414
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.
Klinger B; Jensen LT; Silbergeld A; Laron Z
Clin Endocrinol (Oxf); 1996 Oct; 45(4):423-9. PubMed ID: 8959080
[TBL] [Abstract][Full Text] [Related]
16. Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency: a potential marker of bone growth and response to GH therapy.
Kanzaki S; Hosoda K; Moriwake T; Tanaka H; Kubo T; Inoue M; Higuchi J; Yamaji T; Seino Y
J Clin Endocrinol Metab; 1992 Oct; 75(4):1104-9. PubMed ID: 1400878
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of collagen synthesis and linear growth by growth hormone in glucocorticoid-treated children.
Allen DB; Goldberg BD
Pediatrics; 1992 Mar; 89(3):416-21. PubMed ID: 1741214
[TBL] [Abstract][Full Text] [Related]
18. Renal handling of phosphate can predict height velocity during growth hormone therapy for short children.
Nishiyama S; Ikuta M; Nakamura T; Tomoeda S; Matsuda I
J Clin Endocrinol Metab; 1992 Apr; 74(4):906-9. PubMed ID: 1548358
[TBL] [Abstract][Full Text] [Related]
19. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
[TBL] [Abstract][Full Text] [Related]
20. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
